SavedAdd your journal

Journals / Journal of advances in vetbio science and techniques / 2026 / Issue: 2

The role of chrysin on oxidative stress and the asymmetric dimethylarginine/ dimethylarginine dimethylaminohydrolase-1/nitric oxide synthase signaling pathway in an experimental hyperthyroidism model

Gözde Arkalı(FIRAT ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ)0000-0002-0850-7557
Rana Çakmak(FIRAT UNIVERSITY, FACULTY OF VETERINARY MEDICINE)0009-0004-8629-6224
Merve Oray(FIRAT UNIVERSITY, FACULTY OF VETERINARY MEDICINE, VETERINARY MEDICINE PR.)0009-0008-6981-0489
Beyza Nur Duran(FIRAT UNIVERSITY, FACULTY OF VETERINARY MEDICINE, VETERINARY MEDICINE PR.)0009-0004-7846-753X
Fatma Beril Koçyiğit(HARRAN UNIVERSITY, BİRECİK VOCATIONAL SCHOOL)0000-0001-5659-394X
Muhammed Kerem Şener(FIRAT UNIVERSITY, INSTITUTE OF HEALTH SCIENCES)0009-0006-8588-5865
Pages
—
Publication Date
2026-10-08
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that chrysin may represent a potential protective agent against hyperthyroidism-induced cardiac damage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The present study aimed to investigate the effects of chrysin on oxidative stress parameters and the ADMA/DDAH-1/NOS signaling pathway in rats with experimentally induced hyperthyroidism.
📊
Key Findings & Data:In this study, 10–12-week-old male Sprague–Daw ley rats were used and randomly allocated into five groups: control, solvent, chrysin, hyperthyroid, and hyperthyroid + chrysin.
💡
Conclusion & Impact:These findings suggest that chrysin may represent a potential protective agent against hyperthyroidism-induced cardiac damage.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Chrysin · endothelial dysfunction · heart

Abstract

The present study aimed to investigate the effects of chrysin on oxidative stress parameters and the ADMA/DDAH-1/NOS signaling pathway in rats with experimentally induced hyperthyroidism. In this study, 10–12-week-old male Sprague–Daw ley rats were used and randomly allocated into five groups: control, solvent, chrysin, hyperthyroid, and hyperthyroid + chrysin. Hyperthyroidism was induced by administration of L-thyroxine (0.3 mg/kg/day, i.p.) for eight weeks. Chrysin was administered orally by gavage at dose of 30 mg/kg/day. At the end of the experiment, body and heart weights were record ed, and serum fT3, fT4, and TSH levels were measured. In addition, ADMA, DDAH-1, and eNOS levels, as well as MDA, GSH, CAT, and GSH-Px levels in heart tissue were determined. In the hyperthyroid group, heart weight (p<0.001), serum fT3 (p<0.001) and fT4 (p<0.001) levels, and heart tissue MDA (p<0.01), ADMA (p<0.01), and eNOS (p<0.05) levels were significantly increased, whereas body weight (p<0.001), TSH (p<0.01), GSH (p<0.001), CAT (p<0.05), GSH-Px (p<0.01), and DDAH-1 (p<0.001) levels were significantly decreased. In the hyperthyroid + chrysin group, compared with the hyper thyroid group, heart weight (p<0.001), serum fT3 (p<0.01) and fT4 (p<0.001) levels, as well as heart tissue MDA (p<0.01) and eNOS (p<0.05) levels were decreased, while GSH-Px activity (p<0.01) was increased. Conclusion, hyperthyroidism induced increased oxidative stress in cardiac tissue and disrupted the ADMA/DDAH-1/NOS balance. Chrysin partially ameliorated these adverse alterations through its antioxidant effects and regulatory role in nitric oxide metabolism. These findings suggest that chrysin may represent a potential protective agent against hyperthyroidism-induced cardiac damage.

🔖

Cite This Article

Arkalı, G., Çakmak, R., Oray, M., Duran, B. N., Koçyiğit, F. B., Şener, M. K. (2026). The role of chrysin on oxidative stress and the asymmetric dimethylarginine/ dimethylarginine dimethylaminohydrolase-1/nitric oxide synthase signaling pathway in an experimental hyperthyroidism model. Journal of advances in vetbio science and techniques, Issue: 2. https://doi.org/10.31797/vetbio.1926049

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (44)

  1. Aebi, H. (1984). Catalase in vitro. Methods in Enzymology, 105, 121-126. https://doi.org/10.1016/S0076-6879(84)05016 3.
  2. Al-Nuzaily, M., Tash, F., Farid, M., Al-Habori, M., Bosh nak, H., & Abdelaal, H. (2017). Asymmetric dimethy larginine (Adma): a novel marker of endothelial dysfunc tion in hyperthyroidism. Journal of Blood Disorders, 4(1), 1043. https://doi.org/10.1161/01.cir.98.18.1842.
  3. Araujo, A., Ribeiro, M., Enzveiler, A., Schenkel, P., Fer nandes, T., Partata, W., Irigoyen, M., Llesuy, S., & Belló-Klein, A. (2006). Myocardial antioxidant enzyme activities and concentration and glutathione metabo lism in experimental hyperthyroidism. Molecular and Cellular Endocrinology, 249(1-2), 133-139. https://doi. org/10.1016/j.mce.2006.02.005.
  4. Ateşşahin, A., Karahan, İ., Yılmaz, S., Çeribaşı, A. O., & Bulmuş, Ö. (2006). Lycopene prevents adriamycin-in duced testicular toxicity in rats. Fertility and Sterili ty, 85(1), 1216-1222. https://doi.org/10.1016/j.fertn stert.2005.11.035.
  5. Baltaci, A. (2018). Both experimental hypothyroidism and hyperthyroidism increase cardiac irisin levels in rats. Bratislava Medical Journal, 119(1), 32-35. https://doi. org/10.4149/BLL_2018_007.
  6. Barreto-Chaves, M. L. M., Senger, N., Fevereiro, M. R., Parletta, A. C., & Takano, A. P. C. (2020). Impact of hyperthyroidism on cardiac hypertrophy. Endocrine Con nections, 9(3), R59-R69. https://doi.org/10.1530/EC-19 0543.
  7. Boccalandro, C., Boccalandro, F., Orlander, P., & Wei, C. F. (2003). Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the lit erature. Endocrine Practice, 9(2), 140-146. https://doi. org/10.4158/EP.9.2.140.
  8. Böger, R. H. (2005). Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vascular Medicine, 10(1_suppl), S19-S25. https://doi.org/10.1177/1358836X0501000104.
  9. Buğdaycı, G., & Serin, E. (2005). Asimetrik Dimetilarginin (ADMA). Duzce Medical Journal, 7(2), 36-41.
  10. Dayoub, H., Achan, V., Adimoolam, S., Jacobi, J., Stueh linger, M. C., Wang, B. Y., Tsao, P. S., Kimoto, M., Vallance, P., & Cooke, J. P. (2003). Dimethylarginine dimethylaminohydrolase regulates nitric oxide syn thesis: Genetic and physiological evidence. Circula tion, 108(24), 3042–3047. https://doi.org/10.1161/01. CIR.0000101924.04515.2E.
  11. Dillmann, W. (2002). Cellular action of thyroid hormone on the heart. Thyroid, 12(6), 447-452. https://doi. org/10.1089/105072502760143809.
  12. Dillmann, W. (2010). Cardiac hypertrophy and thyroid hor mone signaling. Heart Failure Reviews, 15(2), 125-132. https://doi.org/10.1007/s10741-008-9125-7
  13. Duggal, J., Singh, S., Barsano, C. P., & Arora, R. (2007). Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management. Journal of The Cardiometabolic Syndrome, 2(3), 198 206. https://doi.org/10.1111/j.1559-4564.2007.06583.x.
  14. Gandhi, G. R., Vasconcelos, A. B. S., Wu, D.-T., Li, H.-B., Antony, P. J., Li, H., Geng, F., Gurgel, R. Q., Narain, N., & Gan, R.-Y. (2020). Citrus flavonoids as promis ing phytochemicals targeting diabetes and related com plications: A systematic review of in vitro and in vivo studies. Nutrients, 12(10), 2907. https://doi.org/10.3390/ nu12102907.
  15. Gao, S., Siddiqui, N., Etim, I., Du, T., Zhang, Y., & Liang, D. (2021). Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmaco kinetics consideration, and ADME mechanisms. Bio medicine & Pharmacotherapy, 142, 112080. https://doi. org/10.1016/j.biopha.2021.112080.
  16. Guyton, A., & Hall, J. (1996). Textbook of medical physiology (9th ed.).WB Saunders Company.
  17. Huo, J., Zhang, M., Wang, X., & Zou, D. (2021). Chrysin induces osteogenic differentiation of human dental pulp stem cells. Experimental Cell Research, 400(2), 112466. https://doi.org/10.1016/j.yexcr.2020.112466.
  18. Karagöz, Y. (2015). Spss 22 uygulamalı biyoistatistik (2. Basım). Nobel Yayınevi.
  19. Karakan, M., & Nazlıkul, H. s. (2017). Oksidatif stres ve ser best radikallerin vücut üzerindeki etkisi. Bilimsel Tama mlayıcı Tıp Regülasyon ve Nöral Terapi Dergisi, 11(2), 7-11.
  20. Kasala, E. R., Bodduluru, L. N., Madana, R. M., Gogoi, R., & Barua, C. C. (2015). Chemopreventive and therapeu tic potential of chrysin in cancer: mechanistic perspec tives. Toxicology Letters, 233(2), 214-225. https://doi. org/10.1016/j.toxlet.2015.01.008
  21. Lawrence, R. A., & Burk, R. F. (1976). Glutathione peroxi dase activity in selenium-deficient rat liver. Biochemical and Biophysical Research Communications, 71(4), 952 958. https://doi.org/10.1016/0006-291X(76)90747-6.
  22. Li, Y., Chen, Tan, Wang, Liang, & Sun. (1998). Impaired re lease of tissue plasminogen activator from the endotheli um in Graves' disease—indicator of endothelial dysfunc tion and reduced fibrinolytic capacity. European Journal of Clinical İnvestigation, 28(12), 1050-1054. https://doi. org/10.1046/j.1365-2362.1998.00381.x.
  23. Maity, S., Kar, D., De, K., Chander, V., & Bandyopadhyay, A. (2013). Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion. Journal of Endocrinology, 217(2), 215-228. https://doi. org/10.1530/JOE-12-0304.
  24. Mani, R., & Natesan, V. (2018). Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry, 145, 187-196. https://doi. org/10.1016/j.phytochem.2017.09.016.
  25. Messarah, M., Saoudi, M., Boumendjel, A., Boulakoud, M. S., & El Feki, A. (2011). Oxidative stress induced by thyroid dysfunction in rat erythrocytes and heart. Envi ronmental Toxicology and Pharmacology, 31(1), 33-41. https://doi.org/10.1016/j.etap.2010.09.003.
  26. Miyamoto, S., Kohno, H., Suzuki, R., Sugie, S., Muraka mi, A., Ohigashi, H., & Tanaka, T. (2006). Preventive effects of chrysin on the development of azoxymeth ane-induced colonic aberrant crypt foci in rats. Oncolo gy Reports, 15(5), 1169-1173. https://doi.org/10.3892/ or.15.5.1169.
  27. Moghadam, E. R., Ang, H. L., Asnaf, S. E., Zabolian, A., Saleki, H., Yavari, M., Esmaeili, H., Zarrabi, A., Ashrafizadeh, M., & Kumar, A. P. (2020). Broad-spec trum preclinical antitumor activity of chrysin: current trends and future perspectives. Biomolecules, 10(10), 1374. https://doi.org/10.3390/biom10101374.
  28. Murphy, R. B., Tommasi, S., Lewis, B. C., & Mangoni, A. A. (2016). Inhibitors of the hydrolytic enzyme dimethylargi nine dimethylaminohydrolase (DDAH): discovery, syn thesis and development. Molecules, 21(5), 615. https:// doi.org/10.3390/molecules21050615.
  29. Naz, S., Imran, M., Rauf, A., Orhan, I. E., Shariati, M. A., Shahbaz, M., Qaisrani, T. B., Shah, Z. A., Plygun, S., & Heydari, M. (2019). Chrysin: Pharmacological and therapeutic properties. Life Sciences, 235, 116797. https://doi.org/10.1016/j.lfs.2019.116797.
  30. Osuna, P. M., Udovcic, M., & Sharma, M. D. (2017). Hy perthyroidism and the heart. Methodist DeBakey Cardio vascular Journal, 13(2), 60-63. https://doi.org/10.14797/ mdcj-13-2-60.
  31. Pingili, R. B., Pawar, A. K., Challa, S. R., Kodali, T., Kop pula, S., & Toleti, V. (2019). A comprehensive review on hepatoprotective and nephroprotective activities of chrysin against various drugs and toxic agents. Chemi co-biological Interactions, 308, 51-60. https://doi. org/10.1016/j.cbi.2019.05.010.
  32. Placer, Z. A., Cushman, L. L., & Johnson, B. C. (1966). Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Analytical Bio chemistry, 16(2), 359-364. https://doi.org/10.1016/0003 2697(66)90167-9.
  33. Prajit, R., Sritawan, N., Suwannakot, K., Naewla, S., Aranarochana, A., Sirichoat, A., Pannangrong, W., Wigmore, P., & Welbat, J. U. (2020). Chrysin protects against memory and hippocampal neurogenesis depletion in D-galactose-induced aging in rats. Nutrients, 12(4), 1100. https://doi.org/10.3390/nu12041100.
  34. Preiser, J. C. (2012). Oxidative stress. Journal of Parenter al and Enteral Nutrition, 36(2), 147-154. https://doi. org/10.1177/0148607111434963.
  35. Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J., Espinola-Klein, C., Jachmann, N., Post, F., Peetz, D., & Bickel, C. (2005). Asym metric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery dis ease: results from the Athero Gene Study. Circulation Research, 97(5), e53-e59. https://doi.org/10.1161/01. RES.0000181286.44222.61.
  36. Sedlak, J., & Lindsay, R. H. (1968). Estimation of total, pro tein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Analytical Biochemistry, 25(1), 192-205. https://doi.org/10.1016/0003-2697(68)90092-4.
  37. Smith, P. E., Krohn, R. I., Hermanson, G., Mallia, A., Gart ner, F., Provenzano, M., Fujimoto, E., Goeke, N., Ol son, B., & Klenk, D. (1985). Measurement of protein us ing bicinchoninic acid. Analytical Biochemistry, 150(1), 76-85. https://doi.org/10.1016/0003-2697(85)90442-7.
  38. Sydow, K., & Münzel, T. (2003). ADMA and oxidative stress. Atherosclerosis Supplements, 4(4), 41-51. https://doi. org/10.1016/S1567-5688(03)00033-3.
  39. Takano, A. P. C., Senger, N., Munhoz, C. D., & Barre to-Chaves, M. L. M. (2018). AT1 receptor blockage impairs NF-κB activation mediated by thyroid hormone in cardiomyocytes. Pflügers Archiv-European Journal of Physiology, 470(3), 549-558. https://doi.org/10.1007/ s00424-017-2088-6.
  40. Tran, C. T., Leiper, J. M., & Vallance, P. (2003). The ddah/ adma/nos pathway. Atherosclerosis Supplements, 4(4), 33-40. https://doi.org/10.1016/S1567-5688(03)00032-1
  41. Türk, G., Ateşşahin, A., Sönmez, M., Çeribaşi, A. O., & Yüce, A. (2008). Improvement of cisplatin-induced in juries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertility and Sterility, 89(5), 1474-1481. https://doi. org/10.1016/j.fertnstert.2007.04.059.
  42. Yen, P. M. (2001). Physiological and molecular basis of thy roid hormone action. Physiological Reviews. 81(3),1097 142. https://doi.org/10.1152/physrev.2001.81.3.1097
  43. Al-Nuzaily, M., Tash, F., Farid, M., Al-Habori, M., Bosh nak, H., & Abdelaal, H. (2017). Asymmetric dimethy larginine (Adma): a novel marker of endothelial dysfunc tion in hyperthyroidism. Journal of Blood Disorders, 4(1), 1043. https://doi.org/10.1161/01.cir.98.18.1842.
  44. Böger, R. H. (2005). Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vascular Medicine, 10(1_suppl), S19-S25. https://doi.org/10.1177/1358836X0501000104.